These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
369 related articles for article (PubMed ID: 30362966)
21. Andexanet alfa: A Novel Factor Xa Inhibitor Reversal Agent. Powell J; Taylor J; Garland SG Ann Pharmacother; 2019 Sep; 53(9):940-946. PubMed ID: 30813754 [No Abstract] [Full Text] [Related]
22. Reversal of Factor Xa Inhibitors by Andexanet Alfa May Increase Thrombogenesis Compared to Pretreatment Values. Siddiqui F; Tafur A; Ramacciotti LS; Jeske W; Hoppensteadt D; Ramacciotti E; Iqbal O; Fareed J Clin Appl Thromb Hemost; 2019; 25():1076029619863493. PubMed ID: 31298056 [TBL] [Abstract][Full Text] [Related]
23. Preclinical safety and efficacy of andexanet alfa in animal models. Lu G; Hollenbach SJ; Baker DC; Tan S; Hutchaleelaha A; Curnutte JT; Conley PB J Thromb Haemost; 2017 Sep; 15(9):1747-1756. PubMed ID: 28682477 [TBL] [Abstract][Full Text] [Related]
24. Andexanet alfa to reverse the anticoagulant activity of factor Xa inhibitors: a review of design, development and potential place in therapy. Sartori M; Cosmi B J Thromb Thrombolysis; 2018 Apr; 45(3):345-352. PubMed ID: 29372400 [TBL] [Abstract][Full Text] [Related]
26. Andexanet alfa for the treatment of hemorrhage. Cervi A; Crowther M Expert Rev Hematol; 2018 Nov; 11(11):847-855. PubMed ID: 30296870 [TBL] [Abstract][Full Text] [Related]
27. Reversal of direct oral anticoagulants: a practical approach. Shih AW; Crowther MA Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):612-619. PubMed ID: 27913536 [TBL] [Abstract][Full Text] [Related]
28. Andexanet Alfa: A Recombinant Modified Human Factor Xa Protein for Drug Reversal of Rivaroxaban and Apixaban. Abuan I; Wong KH; Bolinske B; Hale KS J Pharm Technol; 2019 Jun; 35(3):119-125. PubMed ID: 34860981 [No Abstract] [Full Text] [Related]
29. Reversal agents for direct oral anticoagulants: considerations for hospital physicians and intensivists. Desai NR; Cornutt D Hosp Pract (1995); 2019 Aug; 47(3):113-122. PubMed ID: 31317796 [TBL] [Abstract][Full Text] [Related]
30. Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. Connolly SJ; Crowther M; Eikelboom JW; Gibson CM; Curnutte JT; Lawrence JH; Yue P; Bronson MD; Lu G; Conley PB; Verhamme P; Schmidt J; Middeldorp S; Cohen AT; Beyer-Westendorf J; Albaladejo P; Lopez-Sendon J; Demchuk AM; Pallin DJ; Concha M; Goodman S; Leeds J; Souza S; Siegal DM; Zotova E; Meeks B; Ahmad S; Nakamya J; Milling TJ; N Engl J Med; 2019 Apr; 380(14):1326-1335. PubMed ID: 30730782 [TBL] [Abstract][Full Text] [Related]
31. Low Risk of Traumatic Intracranial Hematoma Expansion with Factor Xa Inhibitors without Andexanet Reversal. Maragkos GA; Nelton EB; Richter S; Stippler M World Neurosurg; 2020 Oct; 142():e95-e100. PubMed ID: 32561488 [TBL] [Abstract][Full Text] [Related]
32. Reversal of apixaban and rivaroxaban with andexanet alfa prior to invasive or surgical procedures. Bradshaw PG; Keegan SP; Droege ME; Dykes NJH; Ernst NE; Foertsch MJ; Makley AT; Mueller EW; Philpott CD; Srinivasan V; Winter JB; Goodman MD; Droege CA Pharmacotherapy; 2022 Oct; 42(10):780-791. PubMed ID: 36073083 [TBL] [Abstract][Full Text] [Related]
33. Andexanet Alfa or Prothrombin Complex Concentrate for Factor Xa Inhibitor Reversal in Acute Major Bleeding: A Systematic Review and Meta-Analysis. Nederpelt CJ; Naar L; Krijnen P; le Cessie S; Kaafarani HMA; Huisman MV; Velmahos GC; Schipper IB Crit Care Med; 2021 Oct; 49(10):e1025-e1036. PubMed ID: 33967205 [TBL] [Abstract][Full Text] [Related]
34. Reversal of Newer Direct Oral Anticoagulant Drugs (DOACs). Hussain SS; Tyroch AH; Mukherjee D Cardiovasc Hematol Agents Med Chem; 2017; 14(2):76-81. PubMed ID: 27215215 [TBL] [Abstract][Full Text] [Related]
35. An 18-month single-center observational study of real-world use of andexanet alfa in patients with factor Xa inhibitor associated intracranial hemorrhage. Giovino A; Shomo E; Busey KV; Case D; Brockhurst A; Concha M Clin Neurol Neurosurg; 2020 Aug; 195():106070. PubMed ID: 32679541 [TBL] [Abstract][Full Text] [Related]
36. Retrospective Comparison of Andexanet Alfa and 4-Factor Prothrombin Complex for Reversal of Factor Xa-Inhibitor Related Bleeding. Stevens VM; Trujillo TC; Kiser TH; MacLaren R; Reynolds PM; Mueller SW Clin Appl Thromb Hemost; 2021; 27():10760296211039020. PubMed ID: 34541920 [TBL] [Abstract][Full Text] [Related]
37. Prevention and Treatment of Bleeding with Direct Oral Anticoagulants. Crawley RM; Anderson RL Drugs; 2020 Sep; 80(13):1293-1308. PubMed ID: 32691292 [TBL] [Abstract][Full Text] [Related]
38. Reversal of Direct Oral Anticoagulants: Current Status and Future Directions. Weitz JI Semin Respir Crit Care Med; 2017 Feb; 38(1):40-50. PubMed ID: 28208197 [TBL] [Abstract][Full Text] [Related]
39. Anticoagulation reversal in the era of the non-vitamin K oral anticoagulants. Enriquez A; Lip GY; Baranchuk A Europace; 2016 Jul; 18(7):955-64. PubMed ID: 25816811 [TBL] [Abstract][Full Text] [Related]
40. A phase 2 PK/PD study of andexanet alfa for reversal of rivaroxaban and edoxaban anticoagulation in healthy volunteers. Lu G; Conley PB; Leeds JM; Karbarz MJ; Levy GG; Mathur VS; Castillo J; Crowther M; Curnutte JT Blood Adv; 2020 Feb; 4(4):728-739. PubMed ID: 32092140 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]